Capital Flow Monitor · Sponsors · CIK 1692147
Abcuro, Inc.
55 CHAPEL ST SUITE 200, NEWTON, MA, 02458 · (617) 714-9759
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$176.5M
Sold
$39.4M
% sold
22.3%
Investors
23
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | D ·current | 506(b) | $176.5M | $39.4M | 22.3% | 23 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- John Alexander Martin — Executive Officer / Director, Newton, MA
- Mark Pruzanski — Director, Newton, MA
- Ron Hunt — Director, Newton, MA
-
Michael Dybbs — Director, Newton, MA
3 other raises
- Claris Biotherapeutics, Inc. $55.7M of $121.5M · 45.9%
- Delfi Diagnostics, Inc. $34.3M of $60.0M · 57.2%
- Samsara Opportunity Fund, L.P. $98.0M of $200.0M · 49.0%
-
Ming Fang — Director, Newton, MA
1 other raise
- Lycia Therapeutics, Inc. $75.0M of $75.0M · 100.0%
- Sarah Boyce — Director, Newton, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.